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Genetic variants of insulin-like growth factor 1 (IGF1) pathway genes have been shown 
to be associated with breast density and IGF1 levels and, therefore, may also influence 
breast cancer risk via pro-survival signaling cascades. The aim of this study was to inves-
tigate associations between IGF1 pathway single nucleotide polymorphisms (SNPs) and 
breast cancer risk among European and East Asian women, and potential interactions 
with menopausal status and breast tumor subtype. Stratified analyses of 1,037 cases 
and 1,050 controls from a population-based case–control study were conducted to 
assess associations with breast cancer for 22 SNPs across 5 IGF1 pathway genes in 
European and East Asian women. Odds ratios were calculated using logistic regres-
sion in additive genetic models. Polytomous logistic regression was used to assess 
heterogeneity by breast tumor subtype. Two SNPs of the IGF1 gene (rs1019731 and 
rs12821878) were associated with breast cancer risk among European women. Four 
highly linked IGF1 SNPs (rs2288378, rs17727841, rs7136446, and rs7956547) were 
modified by menopausal status among East Asian women only and associated with 
postmenopausal breast cancers. The association between rs2288378 and breast can-
cer risk was also modified by breast tumor subtype among East Asian women. Several 
IGF1 polymorphisms were found to be associated with breast cancer risk and some of 
these associations were modified by menopausal status or breast tumor subtype. Such 
interactions should be considered when assessing the role of these variants in breast 
cancer etiology.
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inTrODUcTiOn
The insulin-like growth factor 1 (IGF1) signaling pathway has been implicated in normal cell 
growth, development, and differentiation in the mammary gland and other tissues (1, 2). 
Stimulation by growth hormone (GH) results in the production of IGF1, primarily in the liver. 
While IGF1 mediates its action through the insulin-like growth factor 1 receptor (IGF1R), its 
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bioavailability is regulated by its binding proteins (IGFBPs). 
Over 90% of circulating IGF1 is bound by IGFBPs, with most 
being bound to insulin-like growth factor binding protein 3 
(IGFBP3) (3). Downstream of IGF1R, signaling transmission by 
insulin receptor substrate 1 (IRS1) activates multiple intracel-
lular signaling pathways that mediate the actions of IGF1. The 
two major pathways are the phosphoinositide 3-kinase (PI3K)/
protein kinase B (Akt) pathway and the Ras/mitogen-activated 
protein kinase (MAPK) pathway (4).
Insulin-like growth factor 1 is suggested to play a role in the 
progression of many cancers, including prostate (5, 6), colorectal 
(7, 8), and breast (6, 9), as its pro-survival signaling pathways may 
encourage the proliferation of cancer cells (10). Epidemiological 
studies have previously demonstrated that elevated IGF1 con-
centrations are associated with increased risk of premenopausal 
breast cancer (11, 12), and current evidence also suggests similar 
associations between IGF1 concentrations and postmenopausal 
breast cancers (9). However, these associations may be restricted 
to estrogen receptor (ER)-positive tumors (9), mediated by syner-
gistic growth effects from interactions between the estrogen and 
IGF1 signaling pathways when both are stimulated (13). Studies 
have also implicated IGFBP3 in breast cancer risk (6, 11, 12), 
although it is unclear whether this is a result of IGF-dependent 
or -independent functions (1).
Variants of the IGF1 (14–16), IGFBP3 (12, 14–17), IGF1R 
(18, 19), and PI3KCB (18) genes have been implicated in changes 
in circulating IGF1 and IGFBP3 levels, and may have systemic 
effects in the regulation of the IGF1 signaling pathway. However, 
the evidence for a relationship between variants in IGF-related 
genes and risk of breast cancer is less compelling. While some 
studies have identified associations with breast cancer risk for 
certain variants of IGF-related genes (15, 20–22), the Breast and 
Prostate Cancer Cohort Consortium (BPC3) genotyped 550 
single nucleotide polymorphisms (SNPs) across 24 IGF1 pathway 
genes in a population of predominantly Caucasian postmenopau-
sal women, but found no association with breast cancer risk (23). 
However, assessment of these associations in other ethnic groups 
and in premenopausal women, along with consideration of breast 
tumor subtypes, remains to be conducted.
We examined the associations of 22 polymorphisms across five 
IGF1 pathway genes (IGF1, IGFBP3, IGF1R, IRS1, and PI3KCB) 
with risk of breast cancer among women of European and East 
Asian descent. Potential interactions between IGF-related genes 
and menopausal status and breast tumor subtype were also 
assessed.
MaTerials anD MeThODs
study Population
To investigate the associations between IGF1 pathway genes 
and breast cancer risk, data from the Canadian Breast Cancer 
Study, previously known as the Molecular Epidemiology of 
Breast Cancer (MEBC) Study as described (24), were used. 
In brief, a case–control study was conducted in Vancouver, BC, 
and Kingston, ON, Canada. Incident cases from Vancouver 
and surrounding communities (n = 1,001) were recruited from 
the BC Cancer Registry and comprised women aged 40–80 
newly diagnosed with in  situ or invasive breast cancer with no 
previous history of cancer (except non-melanoma skin cancer). 
Age frequency-matched cancer-free controls (n =  1,014) were 
recruited from the Screening Mammography Program of BC. 
In Kingston, both cases (n =  131) and age frequency-matched 
controls (n =  163) were recruited from the Hotel Dieu Breast 
Assessment Program. All participants completed a questionnaire, 
either self-administered or by telephone interview, and provided 
a biological sample, either blood or saliva. Sufficient DNA for 
genotyping was extracted from blood and saliva samples for 
92% of participants (n =  2,127) in the study. Pathologic data 
concerning tumor ER, progesterone receptor (PgR), and human 
epidermal growth factor receptor 2 (HER2) expression were 
obtained for most cases (n =  997, 96%) from both Vancouver 
and Kingston. Written informed consent was obtained from all 
participants and ethical approval for this study was obtained 
from the University of British Columbia  –  BC Cancer Agency 
Clinical Research Ethics Board and the Queen’s University Health 
Sciences Research Ethics Board.
Data collection
Study Questionnaire
The questionnaire completed by participants provided informa-
tion regarding geographic ancestry; menopausal status; educa-
tion; health, medical, and reproductive history; family history of 
cancer; lifestyle characteristics, including lifetime tobacco and 
alcohol consumption; and lifetime physical activity.
SNP Genotype Data
Genes involved in the synthesis (IGF1), bioavailability (IGFBP3), 
and downstream signaling (IGF1R, IRS1, PI3KCB) of IGF1 were 
selected. Based on suspected relationships with breast cancer risk 
or disease susceptibility from existing literature and using SNP 
tagging methods, a set of 28 SNPs were selected for genotyping. 
Selection of tagSNPs, using the CEU population from HapMap 
release 28 with a minimum minor allele frequency (MAF) 
of 0.10 and r2 threshold of 0.8, was conducted for three genes 
(IGF1, IGFBP3, and PI3KCB) using Tagger (25) in Haploview 
(26). Included in a 768-plex Illumina Golden Gate assay among 
SNPs related to other hypotheses were 11 SNPs of IGF1: rs6214, 
rs1549593 (15), rs17727841, rs2288378, rs7136446, rs2195239, 
rs7956547, rs1019731, rs12821878, rs1520220 (17), and 
rs2162679; 7 SNPs of IGFBP3: rs6670, rs2453839, rs3110697 (27), 
rs2471551 (15, 27), rs2132572 (15), rs10255707, and rs2854744 
(15, 27, 28); 4 SNPs of IGF1R: rs951715 (29), rs2229765 (18, 
29), rs8038415 (30), and rs9672965; 1 SNP of IRS1: rs1801278 
(17); and 5 SNPs of PI3KCB: rs12493155, rs524164, rs10513055, 
rs361072 (17, 18), and rs693293. Genotyping was performed by 
the Genome Quebec/McGill University Innovation Centre in 
Montreal, Canada.
Quality control of genotype data was performed in Genome 
Studio v2011.1 (Illumina, San Diego, CA, USA), PLINK v1.07 
(31), GRR (32), and Excel 2007 (Microsoft, Redmond, WA, 
USA), and has been previously described (24). Briefly, SNPs were 
excluded if they exhibited Gencall Scores <0.25, had GenTrain 
TaBle 1 | selected characteristics of study participants.
cases (n = 1037) controls (n = 1050)
Mean (sD)/N(%) Mean (sD)/N(%)
Age 57.0 (10.3) 56.5 (10.1)
Body mass index (kg/m2) 25.6 (5.4) 25.0 (4.7)
Ethnicity
European 641 (61.8%) 806 (76.8%)
East Asian 305 (29.4%) 168 (16.0%)
South Asian 31 (3.0%) 31 (2.9%)
Mixed/other 60 (5.8%) 45 (4.3%)
Household income
<$30,000 181 (17.5%) 104 (9.9%)
$30,000–$59,999 255 (24.6%) 230 (21.9%)
$60,000–$99,999 229 (22.1%) 262 (25.0%)
>$100,000 221 (21.3%) 310 (29.5%)
Not stated 151 (14.6%) 144 (13.7%)
Education
High school or less 353 (34.3%) 259 (24.7%)
College/trade certificate 312 (30.3%) 310 (29.6%)
Undergraduate degree 244 (23.7%) 271 (25.9%)
Graduate/professional 
degree
121 (11.7%) 207 (19.8%)
Menopausal status
Premenopausal 351 (33.9%) 391 (37.2%)
Postmenopausal 684 (66.1%) 659 (62.8%)
Reproductive history
Age at menarche (years) 12.9 (1.6) 12.8 (1.5)
Ever been pregnant 856 (82.8%) 825 (78.7%)
Age at first birth (years) 27.8 (5.4) 27.7 (5.3)
Number of pregnancies 2.3 (1.7) 2.2 (1.7)
Age at first mammogram 
(years)
44.5 (8.6) 42.7 (7.4)
Family history of breast cancer 204 (19.7%) 145 (13.8%)
Current smoker 66 (6.4%) 62 (5.9%)
Pack-years smoking 5.7 (12.3) 5.1 (10.9)
Lifetime alcohol consumption (#drinks/week)
Teen 1.1 (3.7) 1.6 (4.0)
20s 2.6 (5.5) 3.9 (8.1)
30s 2.9 (6.1) 3.5 (5.4)
40s 3.2 (6.1) 3.7 (5.6)
50s 2.8 (4.9) 3.8 (6.2)
Last 2 years 2.1 (4.5) 2.9 (5.0)
Moderate-to-vigorous physical activity (MET-hours/week)
Leisure time 14.5 (19.0) 23.0 (32.3)
Household 39.7 (58.5) 48.9 (83.1)
Occupational 54.4 (76.8) 45.4 (66.4)
Medication use
Oral contraceptive 570 (55.0%) 695 (66.2%)
Hormone replacement 
therapy
327 (31.7%) 351 (33.5%)
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scores <0.4, exhibited poor clustering, were mono-allelic, showed 
genotype discrepancies in 126 pairs of replicate samples, had 
call rates <0.95, had unexpectedly low MAF among Caucasian 
controls in comparison to HapMap CEU data, or violated the 
Hardy–Weinberg equilibrium (p < 0.001) in European-ancestry 
controls. Relevant to this analysis, six SNPs were excluded follow-
ing quality control: two by the genotyping center (rs1520220 and 
rs2854744), two for poor clustering (rs9672965 and rs693293), 
one for low call rate (rs10255707), and one for discrepancies in 
replicate samples (rs2162679). Therefore, final analyses included 
22 IGF1 pathway SNPs.
Exclusion criteria for samples included call rate <0.95 
(n = 14); unrelated samples having identical genotypes (n = 6); 
sex discrepancy, as identified by Y chromosome markers, 
indicating that the sample was male (n =  1); excess heterozy-
gosity, specifically >3 SDs from the mean of other samples of 
the same ethnicity (n = 4); discrepancies between self-reported 
ethnicity and predicted ethnicity from genotype data (n = 5). If 
participants in the study were related, one was excluded (n = 9). 
Questionnaire data were used to verify that nine pairs of samples 
were from relatives. If the pairs were both cases, the individual 
with the later diagnosis date was excluded; if the pairs were both 
controls, the individual with the younger age was excluded. To 
compare self-reported ethnicity to predicted ethnicity, identity-
by-state was calculated and multi-dimensional scaling plots (31) 
were created with HapMap samples selected from the CEU, CHB, 
CHD, JPT, YRI, and TSI populations. A total of 1,037 cases and 
1,050 controls remained after quality control procedures.
assessment of Tumor Biomarkers
ER, PgR, and HER2 status of all invasive tumors was determined 
using immunohistochemistry (IHC), supplemented by fluores-
cence in situ hybridization (FISH) if the IHC results for HER2 
were equivocal. Tumors were grouped according to biomarker 
status, regardless of intensity of expression. Four breast tumor 
subtypes were identified: ER+ and/or PgR+/HER2−, ER+ 
and/or PgR+/HER2+, ER−/PgR−/HER2+, and ER−/PgR−/
HER2−.
statistical analyses
Relationships between SNPs and breast cancer risk were inves-
tigated using unconditional logistic regression in an additive 
genetic model adjusted for age and center. All analyses were 
stratified by ethnicity and conducted in the two largest sub-
groups: Europeans and East Asians (Chinese, Japanese, Korean, 
and Filipino). The Benjamini–Hochberg adjustment (33) was 
used to control the FDR across all SNPs and provide corrected 
p-values. SNPs with a q-value (FDR adjusted p-value) <0.05 
were considered statistically significant. Modification of these 
relationships by menopausal status was assessed by including an 
interaction term. Case–case polytomous logistic regression was 
used to assess heterogeneity of odds ratios between hormone 
receptor- and HER2-defined tumor subtypes. Assessment for 
these interactions was restricted to SNPs with p-value <0.1 for 
an association with breast cancer risk prior to false discovery 
rate (FDR) adjustment and MAF among controls >0.1 in 
each respective ethnic subgroup. All analyses were performed 
using  SAS (Version 9.4, SAS Institute, Cary, NC, USA) and 
PLINK (31).
resUlTs
Characteristics of the study participants are presented in 
Table 1. In brief, approximately two-thirds of participants were 
TaBle 2 | Minor allele frequencies (MaF) and age- and center-adjusted odds ratios for the associations between snPs in insulin-like growth factor 
signaling genes and breast cancer risk.
gene snP location Major 
allele
Minor 
allele
european (641 cases, 806 controls) east asian (305 cases, 168 controls)
MaF  
(controls)
Odds ratio p-value q-valuea MaF 
(controls)
Odds ratio p-value q-valuea
IGF1 rs6214 3′UTR G A 0.43 0.90 (0.77, 1.04) 0.16 0.47 0.49 0.83 (0.63, 1.09) 0.17 0.44
IGF1 rs1549593 Intron C A 0.16 0.76 (0.61, 0.95) 0.01 0.11 0.02 0.72 (0.25, 2.13) 0.56 0.68
IGF1 rs17727841 Intron C G 0.19 1.00 (0.82, 1.21) 0.96 0.99 0.19 0.73 (0.51, 1.03) 0.07 0.39
IGF1 rs2288378 Intron G A 0.25 1.06 (0.89, 1.26) 0.52 0.82 0.19 0.71 (0.50, 1.01) 0.06 0.39
IGF1 rs7136446 Intron A G 0.42 1.09 (0.93, 1.26) 0.29 0.61 0.19 0.71 (0.50, 1.01) 0.06 0.39
IGF1 rs2195239 Intron G C 0.25 0.98 (0.83, 1.17) 0.84 0.98 0.46 0.94 (0.72, 1.23) 0.65 0.75
IGF1 rs7956547 Intron A G 0.27 0.97 (0.82, 1.15) 0.71 0.89 0.18 0.71 (0.50, 1.02) 0.07 0.39
IGF1 rs1019731b Intron C A 0.15 0.67 (0.53, 0.84) <0.01 0.01 0.00 N/A N/A N/A
IGF1 rs12821878c Intron G A 0.24 0.73 (0.61, 0.88) <0.01 0.01 0.04 1.25 (0.63, 2.49) 0.53 0.68
IGFBP3 rs6670 3′UTR A T 0.23 0.95 (0.80, 1.14) 0.57 0.84 0.01 2.41 (0.82, 7.06) 0.11 0.40
IGFBP3 rs2453839 Intron A G 0.19 1.04 (0.87, 1.25) 0.66 0.89 0.24 0.83 (0.60, 1.14) 0.24 0.49
IGFBP3 rs3110697 Intron G A 0.43 0.93 (0.80, 1.08) 0.36 0.66 0.29 0.86 (0.64, 1.15) 0.30 0.55
IGFBP3 rs2471551 Intron G C 0.22 0.90 (0.75, 1.08) 0.26 0.61 0.02 1.77 (0.74, 4.24) 0.20 0.44
IGFBP3 rs2132572 Promoter 
region
G A 0.21 1.00 (0.84, 1.20) 0.99 0.99 0.25 0.81 (0.59, 1.11) 0.18 0.44
IGF1R rs951715 Intron A G 0.34 1.14 (0.98, 1.33) 0.08 0.36 0.50 0.89 (0.68, 1.16) 0.38 0.59
IGF1R rs2229765 Exond G A 0.44 1.03 (0.89, 1.19) 0.73 0.89 0.33 0.99 (0.74, 1.32) 0.95 0.99
IGF1R rs8038415 Intron A G 0.49 1.00 (0.86, 1.15) 0.95 0.99 0.46 1.22 (0.93, 1.60) 0.15 0.44
IRS1 rs1801278 Exone G A 0.06 1.17 (0.87, 1.57) 0.31 0.61 0.02 0.39 (0.13, 1.16) 0.09 0.39
PI3KCB rs12493155 Intron G A 0.45 1.07 (0.92, 1.23) 0.40 0.67 0.48 0.88 (0.68, 1.15) 0.35 0.59
PI3KCB rs524164 Intron G A 0.47 0.90 (0.78, 1.04) 0.16 0.47 0.02 0.70 (0.26, 1.92) 0.49 0.68
PI3KCB rs10513055 Intron A C 0.23 0.85 (0.71, 1.01) 0.07 0.36 <0.01 0.58 (0.04, 9.37) 0.70 0.77
PI3KCB rs361072 Intron A G 0.47 0.90 (0.78, 1.05) 0.17 0.47 0.02 0.70 (0.26, 1.92) 0.49 0.68
SNPs with a q-value <0.05 are presented in bold.
aFalse discovery rate-adjusted p-value.
bGenotype frequencies of nCC = 509, nAC = 125, and nAA = 7 among European cases; nCC = 578, nAC = 210, and nAA = 18 among European controls.
cGenotype frequencies of nGG = 421, nAG = 195, and nAA = 25 among European cases; nGG = 461, nAG = 301, and nAA = 44 among European controls.
dSynonymous mutation.
eGly/Arg substitution.
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women of European descent and one-quarter were of East Asian 
descent, although a greater proportion of cases were East Asian 
compared to controls. On average, breast cancer cases also had 
lower household income, were less likely to have completed 
postsecondary education, were older at their first mammo-
gram, were more likely to have a primary family history of 
breast cancer and consumed less alcohol over their lifetime 
than controls.
Relationships between SNPs and breast cancer risk among 
European and East Asian women are presented in Table  2. In 
the European group, the minor A-allele of three IGF1 SNPs 
(rs1549593, rs1019731, and rs12821878) was associated with 
decreased risk of breast cancer, but only two of these SNPs 
passed adjustment for the FDR: rs1019731 (OR  =  0.67, 95% 
CI: 0.53–0.84) and rs12821878 (OR = 0.73, 95% CI: 0.61–0.88). 
Among East Asians, no SNP was associated with breast cancer 
risk even prior to FDR adjustment.
Analyses further stratified by menopausal status are presented 
in Table 3. Among European women, no effect modification was 
detected. However, there was suggested modification by meno-
pausal status for the rs1801278 polymorphism in the IRS1 gene 
(interaction p-value, pint = 0.06), which appeared to decrease the 
risk of premenopausal, while increasing the risk of postmeno-
pausal breast cancers. Among East Asian women, modification 
of genetic effect by menopausal status was apparent for four 
IGF1 SNPs: rs17727841, rs2288378, rs7136446, and rs7956547 
(pint <  0.01 for all), although these SNPs were in high linkage 
disequilibrium (LD) (r2 = 0.86–0.98). The minor alleles of these 
SNPs were associated with decreased risk of breast cancer among 
postmenopausal women.
Lastly, heterogeneity in odds ratios between breast tumor 
subtypes for select IGF1 pathway SNPs among European and 
East Asian women are presented in Table 4. In European women, 
heterogeneity between tumor subtypes was not observed for any 
of the five SNPs that were examined. In East Asian women, tumor 
heterogeneity was observed for rs2288378 (pTH = 0.04), in which 
a decreased risk of ER+ and/or PgR+/HER2− tumors, but not 
other tumor subtypes, was noted.
DiscUssiOn
In our analyses of European and East Asian women, we observed 
associations between select IGF1 SNPs and breast cancer risk in 
both European and East Asian women. In Europeans, the minor 
alleles of two IGF1 SNPs (rs1019731 and rs12821878) were 
associated with reduced breast cancer risk. In East Asians, the 
association between four IGF1 SNPs (rs17727841, rs2288378, 
rs7136446, and rs7956547) in high LD and breast cancer risk 
was modified by menopausal status and the minor alleles of 
these SNPs were associated with decreased risk of postmeno-
pausal breast cancer. Lastly, heterogeneity by tumor subtype for 
rs2288378 was observed in East Asian women.
TaBle 3 | selected interactions of menopausal status and igF1 pathway snPs on breast cancer risk among european and east asian women.
gene snP european
Or (95% ci)
east asian
Or (95% ci)
Premenopausal  
(189 cases, 275 controls)
Postmenopausal 
(451 cases, 531 controls)
pinta Premenopausal 
(127 cases, 79 controls)
Postmenopausal 
(178 cases, 89 controls)
pinta
IGF1 rs6214 1.01 (0.77, 1.31) 0.85 (0.70, 1.02) 0.32 0.97 (0.65, 1.45) 0.68 (0.46, 0.99) 0.14
IGF1 rs1549593 0.95 (0.65, 1.40) 0.69 (0.53, 0.89) 0.17 0.83 (0.18, 3.81) 0.66 (0.14, 3.03) 0.84
IGF1 rs17727841b 0.97 (0.67, 1.41) 1.00 (0.80, 1.26) 0.89 1.31 (0.76, 2.26) 0.44 (0.27, 0.72) <0.01
IGF1 rs2288378c 0.91 (0.65, 1.26) 1.12 (0.91, 1.38) 0.30 1.31 (0.76, 2.26) 0.43 (0.26, 0.69) <0.01
IGF1 rs7136446d 0.90 (0.69, 1.19) 1.17 (0.97, 1.41) 0.13 1.25 (0.73, 2.13) 0.45 (0.28, 0.72) <0.01
IGF1 rs2195239 1.07 (0.77, 1.48) 0.95 (0.77, 1.17) 0.55 1.00 (0.66, 1.53) 0.89 (0.62, 1.27) 0.66
IGF1 rs7956547e 0.97 (0.71, 1.33) 0.97 (0.79, 1.19) 0.99 1.25 (0.72, 2.17) 0.45 (0.28, 0.73) <0.01
IGF1 rs1019731 0.66 (0.44, 1.00) 0.67 (0.52, 0.88) 0.93 N/A N/A N/A
IGF1 rs12821878 0.66 (0.48, 0.92) 0.77 (0.62, 0.96) 0.45 1.24 (0.47, 3.27) 1.28 (0.48, 3.41) 0.97
IGFBP3 rs6670 0.80 (0.58, 1.11) 1.02 (0.82, 1.27) 0.20 N/A 1.40 (0.43, 4.52) N/A
IGFBP3 rs2453839 0.98 (0.71, 1.36) 1.08 (0.86, 1.35) 0.65 0.85 (0.55, 1.33) 0.82 (0.52, 1.29) 0.89
IGFBP3 rs3110697 0.96 (0.73, 1.27) 0.92 (0.77, 1.10) 0.79 0.93 (0.60, 1.44) 0.79 (0.52, 1.19) 0.58
IGFBP3 rs2471551 0.83 (0.60, 1.15) 0.94 (0.75, 1.17) 0.52 7.42 (0.94, 58.67) 0.91 (0.33, 2.56) 0.08
IGFBP3 rs2132572 1.14 (0.81, 1.59) 0.95 (0.77, 1.17) 0.36 0.79 (0.51, 1.23) 0.82 (0.52, 1.30) 0.91
IGF1R rs951715 1.34 (1.03, 1.75) 1.05 (0.87, 1.26) 0.13 0.83 (0.57, 1.21) 0.97 (0.67, 1.40) 0.56
IGF1R rs2229765 1.10 (0.84, 1.43) 1.00 (0.84, 1.19) 0.60 0.82 (0.54, 1.23) 1.22 (0.81, 1.84) 0.17
IGF1R rs8038415 0.96 (0.74, 1.24) 0.98 (0.82, 1.17) 0.70 1.00 (0.68, 1.48) 1.48 (1.01, 2.17) 0.15
IRS1 rs1801278 0.77 (0.45, 1.31) 1.44 (1.00, 2.08) 0.06 0.31 (0.03, 3.43) 0.40 (0.12, 1.34) 0.85
PI3KCB rs12493155 1.13 (0.87, 1.46) 1.04 (0.87, 1.24) 0.61 0.92 (0.61, 1.38) 0.85 (0.60, 1.20) 0.77
PI3KCB rs524164 0.87 (0.68, 1.13) 0.92 (0.77, 1.10) 0.75 0.23 (0.04, 1.23) 1.78 (0.36, 8.75) 0.09
PI3KCB rs10513055 0.82 (0.59, 1.13) 0.87 (0.70, 1.08) 0.76 N/A N/A N/A
PI3KCB rs361072 0.87 (0.67, 1.12) 0.92 (0.77, 1.10) 0.70 0.23 (0.04, 1.23) 1.78 (0.36, 8.75) 0.09
SNPs with a p-value for interaction by menopausal status are presented in bold.
ap-value for interaction by menopausal status. 
bGenotype frequencies of nCC = 86, nCG = 37, and nGG = 4 among premenopausal East Asian cases; nCC = 60, nCG = 16, and nGG = 3 among premenopausal East Asian controls; 
nCC = 141, nCG = 33, and nGG = 4 among postmenopausal East Asian cases; nCC = 52, nCG = 33, and nGG = 4 among postmenopausal East Asian controls.
cGenotype frequencies of nGG = 86, nAG = 37, and nAA = 4 among premenopausal East Asian cases; nGG = 60, nAG = 16, and nAA = 3 among premenopausal East Asian controls; 
nGG = 141, nAG = 33, and nAA = 4 among postmenopausal East Asian cases; nGG = 51, nAG = 34, and nAA = 4 among postmenopausal East Asian controls.
dGenotype frequencies of nAA = 86, nAG = 37, and nGG = 4 among premenopausal East Asian cases; nAA = 59, nAG = 17, and nGG = 3 among premenopausal East Asian controls; 
nAA = 139, nAG = 35, and nGG = 4 among postmenopausal East Asian cases; nAA = 51, nAG = 34, and nGG = 4 among postmenopausal East Asian controls.
eGenotype frequencies of nAA = 87, nAG = 37, and nGG = 3 among premenopausal East Asian cases; nAA = 60, nAG = 16, and nGG = 3 among premenopausal East Asian controls; 
nAA = 141, nAG = 33, and nGG = 4 among postmenopausal East Asian cases; nAA = 52, nAG = 34, and nGG = 3 among postmenopausal East Asian controls.
TaBle 4 | heterogeneity in odds ratios between breast tumour subtypes for select igF1 pathway snPs among european and east asian women.
ethnicity gene snP genotype Tumor subtype pTha
er+ and/or Pgr+/her2+ er+ and/or Pgr+/her2− er−/Pgr−/her2+ er−/Pgr−/her2−
n Or (95% ci) n Or (95% ci) n Or (95% ci) n Or (95% ci)
European IGF1 rs1549593 CC 56 0.82 (0.50, 1.36) 307 0.74 (0.57, 0.96) 25 0.64 (0.29, 1.44) 84 0.76 (0.50, 1.17) 0.96
AC 16 93 7 26
AA 2 3 0 1
European IGF1 rs1019731 CC 62 0.49 (0.26, 0.89) 320 0.65 (0.50, 0.85) 25 0.67 (0.30, 1.50) 87 0.76 (0.50, 1.17) 0.68
AC 12 82 7 21
AA 0 2 0 3
European IGF1 rs12821878 GG 52 0.61 (0.39, 0.96) 270 0.70 (0.57, 0.87) 20 0.71 (0.38, 1.35) 70 0.81 (0.57, 1.15) 0.79
AG 20 118 12 36
AA 2 16 0 5
European IGF1R rs951715 AA 22 1.60 (1.14, 2.24) 167 1.14 (0.96, 1.36) 12 1.14 (0.69, 1.91) 46 0.98 (0.73, 1.31) 0.16
AG 36 172 16 55
GG 16 65 4 10
European PI3KCB rs10513055 AA 49 0.74 (0.48, 1.15) 260 0.81 (0.66, 1.00) 16 1.11 (0.62, 1.99) 64 1.00 (0.71, 1.39) 0.45
AC 23 130 16 43
CC 2 14 0 4
East 
Asian
IGF1 rs2288378 gg 24 0.86 (0.44, 1.66) 148 0.54 (0.35, 0.82) 7 1.24 (0.49, 3.17) 37 1.15 (0.68, 1.93) 0.04
ag 12 37 6 11
aa 0 2 0 6
SNPs with a p-value for tumour heterogeneity are presented in bold.
ap-value for tumor heterogeneity in odds ratio by breast tumor subtype.
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An association between SNPs of the IGF1 pathway and breast 
cancer risk has been hypothesized due to the role of circulating 
IGF1 levels and the IGF1 signaling pathway in risk of breast 
cancer (3, 9, 23). Variants of the IGF1 gene, which encodes the 
IGF1 protein, are associated with increased circulating IGF1 
levels (14–16) and increased percent breast density (17, 34, 35). 
However, studies on its association with breast cancer risk have 
been less conclusive. Our study observed associations between 
two IGF1 SNPs, rs1019731 and rs12821878, and breast cancer 
risk among European women; however, a study from the Breast 
and Prostate Cancer Cohort Consortium reported no associa-
tion with breast cancer risk for these SNPs (23). A study by 
Verheus et al. evaluated the relationship between IGF1 variants 
and mammographic density, and reported that the rs12821878 
minor allele may be associated with decreased mammographic 
density (36), which is congruous with the decrease in risk we 
observed.
Similarly, the IGFBP3, IGF1R, IRS1, and PI3KCB genes have a 
purported relationship with breast cancer risk due to either their 
role in IGF1 signaling regulation (15, 18, 27), or association with 
strong breast cancer risk factors (17, 28). However, our null results 
with regard to the relationship between variants of the IGFBP3, 
IGF1R, IRS1, and PI3KCB genes and, overall, premenopausal and 
postmenopausal breast cancer risk in European and East Asian 
women are in concordance with the findings from analyses in 
the Breast and Prostate Cancer Cohort Consortium (23, 37) and 
recent GWAS publications (38, 39).
We observed modification of associations with breast cancer 
risk by menopausal status for four IG1 SNPs (rs17727841, 
rs2288378, rs7136446, and rs7956547) in high LD among East 
Asian women. Menopause-associated declines in IGF1 levels 
have been previously reported (40, 41) and may explain our 
findings, and is corroborated by reported effect modification by 
menopausal status of associations between breast cancer risk fac-
tors, such as age, recent leisure-time physical activity and alcohol 
consumption, and IGF1 and IGFBP3 levels (42). However, the 
decrease in risk as a result of these SNPs among postmenopausal 
East Asian women is incongruent with the literature. A meta-
analysis reported that IGF1 levels were approximately 7 ng/mL 
higher among individuals carrying at least one minor allele at 
the rs7136446 polymorphism compared to homozygous carriers 
of the major allele (43). Genotype imputation of this SNP in 
another study produced similar findings (16). Increased IGF1 
levels would presumably lead to increased risk of breast cancer; 
however, our study found the opposite direction of effect.
Analyses by breast tumor subtype revealed potential hetero-
geneity for rs2288378, representing the four high-LD IGF1 SNPs, 
decreasing risk of only ER+ and/or PgR+/HER2− tumors by 
approximately 45% among East Asian women. One study sug-
gests that positive associations between IGF1 concentrations and 
breast cancer risk may be restricted to ER+ tumors (9), which 
may explain why stronger associations were observed for ER+ 
and/or PgR+ tumors in our study. In vitro studies have demon-
strated that the IGF and ER signaling pathways are positively 
reinforced by one another, mediating signaling via the other 
pathway through increasing expression of key signaling path-
way proteins, cross-activation, and stimulating transcriptional 
activation (13, 44, 45). In addition, interactions with HER2 have 
been suggested, as cross-talk between IGF1R and HER2 has been 
implicated in resistance against trastuzumab, a monoclonal anti-
body used in breast cancer treatment to target HER2 receptors 
(46, 47). This extensive network of interactions between IGF1, 
ER, and HER2 signaling pathways, and potential heterogeneity 
of risk by tumor subtype for IGF1 genes observed in our study 
suggest greater complexities in the relationship between IGF1 
pathway genes and breast cancer etiology.
Limitations of our study include limited statistical power in 
stratified and subgroup analyses. Specifically, with the number of 
cases and controls in our European subgroup and after account-
ing for multiple comparisons, we were powered to observe effect 
sizes as low as OR = 1.34 (or OR = 0.75 if protective) for SNPs 
with MAFs of 0.50, and OR = 1.80 (or OR = 0.56 if protective) for 
SNPS with MAFs of 0.05. The small sample sizes in the analyses 
of East Asian women and of tumor subtypes warrant caution 
in the interpretations, and further large studies are needed to 
confirm these findings. Differences in demographic, lifestyle, and 
reproductive factors between cases and controls of the study may 
be partly attributed to the recruitment methods used in BC where 
cases were selected using a population-based cancer registry and 
controls were recruited from a breast mammography program. If 
those who elect to participate in screening programs are different 
than those who do not, there is potential for selection bias to 
be introduced. However, since the study recruitment strategies 
are unlikely to be related to individuals’ genetic variants in IGF 
pathway genes, concerns for selection bias are minimized.
In conclusion, our study observed associations between some 
IGF1 SNPs and breast cancer risk among European and East 
Asian women, although evidence of an association for other 
IGF pathway SNPs was limited. Potential modification of these 
relationships by menopausal status and breast tumor subtype 
may warrant further consideration when assessing molecular 
signaling pathway interactions in the genetic etiology of breast 
cancer.
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